Soleno Therapeutics Inc
SLNO69.610USD
+3.100+4.66%
Handelsschluss 08/26, 16:00（ET）Kurse um 15 Minuten verzögert
3.18BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Soleno Therapeutics Inc Unternehmen
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
Unternehmensinformationen
BörsenkürzelSLNO
Name des UnternehmensSoleno Therapeutics Inc
IPO-datumOct 23, 2014
CEODr. Anish Bhatnagar, M.D.
Anzahl der mitarbeiter92
WertpapierartOrdinary Share
GeschäftsjahresendeOct 23
Addresse100 Marine Parkway, Suite 400
StadtREDWOOD CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94065
Telefon16502138444
Websitehttps://soleno.life/
BörsenkürzelSLNO
IPO-datumOct 23, 2014
CEODr. Anish Bhatnagar, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Meredith Manning
Ms. Meredith Manning
Chief Commercial Officer
Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
9.99%
Vivo Capital, LLC
7.45%
Adage Capital Management, L.P.
6.73%
T. Rowe Price Associates, Inc.
6.43%
Fidelity Management & Research Company LLC
6.07%
Andere
63.33%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
9.99%
Vivo Capital, LLC
7.45%
Adage Capital Management, L.P.
6.73%
T. Rowe Price Associates, Inc.
6.43%
Fidelity Management & Research Company LLC
6.07%
Andere
63.33%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.94%
Investment Advisor/Hedge Fund
34.03%
Hedge Fund
24.38%
Venture Capital
10.62%
Individual Investor
1.82%
Research Firm
1.74%
Pension Fund
1.17%
Private Equity
0.81%
Bank and Trust
0.67%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
384
58.69M
110.44%
+1.14M
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
2023Q1
121
4.63M
57.04%
-249.13K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
5.14M
10.2%
-47.37K
-0.91%
Mar 31, 2025
Vivo Capital, LLC
4.46M
8.85%
-1.83M
-29.14%
Mar 31, 2025
Adage Capital Management, L.P.
4.39M
8.72%
+1.62M
+58.24%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.37M
4.7%
+768.45K
+48.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.12M
4.21%
+1.36M
+179.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
3.4%
-105.47K
-5.79%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
3.69%
-18.21K
-0.97%
Mar 31, 2025
Avoro Capital Advisors LLC
2.52M
5.01%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.58M
3.13%
+603.63K
+62.08%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.21M
2.4%
+329.79K
+37.41%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Invesco Dorsey Wright Healthcare Momentum ETF
3.78%
Harbor Health Care ETF
2.7%
Invesco Dorsey Wright SmallCap Momentum ETF
1.47%
SPDR S&P Biotech ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
JPMorgan Healthcare Leaders ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.66%
First Trust Multi-Manager Small Cap Opportunities ETF
0.32%
T Rowe Price Small-Mid Cap ETF
0.23%
Fidelity Fundamental Small-Mid Cap ETF
0.23%
Mehr Anzeigen
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.78%
Harbor Health Care ETF
Anteil2.7%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil1.47%
SPDR S&P Biotech ETF
Anteil1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.94%
JPMorgan Healthcare Leaders ETF
Anteil0.85%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.66%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.32%
T Rowe Price Small-Mid Cap ETF
Anteil0.23%
Fidelity Fundamental Small-Mid Cap ETF
Anteil0.23%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Datum
Art
Verhältnis
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
